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Clostridium difficile is the most common cause of antibiotic-associated diarrhoea worldwide.
Over the past 10 years, the incidence and severity of disease have increased in North America
and Europe due to the emergence of a hypervirulent clone designated PCR ribotype 027. In this
study, we sought to identify phenotypic differences among a collection of 26 presumed PCR
ribotype 027 strains from the US and the UK isolated between 1988 and 2008 and also re-
evaluated the PCR ribotype. We demonstrated that some of the strains typed as BI by restriction
endonuclease analysis, and presumed to be PCR ribotype 027, were in fact other PCR ribotypes
such as 176, 198 and 244 due to slight variation in banding pattern compared to the 027 strains.
The reassigned 176, 198 and 244 ribotype strains were isolated in the US between 2001 and
2004 and appeared to have evolved recently from the 027 lineage. In addition, the UK strains
were more motile and more resistant to most of the antibiotics compared to the US counterparts.
We conclude that there should be a heightened awareness of newly identified PCR ribotypes
such as 176, 198 and 244, and that they may be as problematic as the notorious 027 strains.
INTRODUCTION
Clostridium difficile is a Gram-positive, anaerobic, spore-
forming bacillus that is the causative agent of C. difficile
infection (CDI) (Bartlett, 1994). CDI is often caused after
broad-spectrum antimicrobial therapy, which disrupts the
barrier effect of the endogenous intestinal microflora
allowing C. difficile spores to germinate, colonize the
gastrointestinal tract and produce toxins, which causes tissue
damage (Just et al., 1995, 2001). Antibiotic resistance is likely
to be important in infection, as it would provide C. difficile a
competitive growth advantage in the gut of patients after
antibiotic treatment (Delaney et al., 2007). Colonization is
also an important step in C. difficile pathogenesis, which
involves various determinants including surface-layer pro-
teins, adhesins (P47, Cwp66 and Fbp68) (Calabi &
Fairweather, 2002; Hennequin et al., 2003; Waligora et al.,
2001) and flagella, which have been implicated in adherence
of C. difficile to caecal mucus in axenic mice (Tasteyre et al.,
2001). Flagella have multiple roles in virulence of other
enteric pathogens including motility through the viscous
intestinal mucosa, chemotaxis, protein secretion and inter-
action with the innate immune system (Feuillet et al., 2006;
Lee et al., 1986; Milton et al., 1996; Moulton & Montie, 1979;
Pruckler et al., 1995).
In the last few years, the appearance of highly virulent and
epidemic C. difficile strains has significantly changed the
epidemiology of CDI in North America and Europe (Kuijper
et al., 2007; Pe´pin et al., 2005). This is largely due to the
emergence of a clonal lineage referred to using different
typing methods as BI [restriction endonuclease analysis
(REA)], NAP1 (PFGE), 027 (PCR ribotype) (Killgore et al.,
2008) and different clusters [multiple-locus variable-number
tandem-repeat analysis (MLVA)] (Eckert et al., 2011). The
hypervirulent NAP1 types can be subtyped as NAP1, NAP1a
or NAP1c variants, whereas there are at least 23 variants of
the REA types, BI-1 to BI-23 (Killgore et al., 2008). MLVA
can subtype in different clusters (Eckert et al., 2011). All
these strains are invariably classified as toxinotype III by
toxinotyping (Rupnik et al., 1998).
The first documented PCR ribotype 027 was described as
an isolate from a Parisian hospital in 1985 (Popoff et al.,
1988). It was occasionally isolated in the 1990s in the US
until major outbreaks of 027-related CDI emerged in 2003
(Morris et al., 2002; Redelings et al., 2007; Ricciardi et al.,
2007). There has been a threefold increase in CDI in the
elderly, largely as a result of the emergence of the 027
strains during 2000–2005 (Jagai & Naumova, 2009). In the
UK, major outbreaks emerged in 2006 where the PCR
ribotype 027 was identified. The proportion of 027 strains
Abbreviations: CDI, Clostridium difficile infection; MLVA, multiple-locus
variable-number tandem-repeat analysis; REA, restriction endonuclease
analysis.
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isolated in UK hospitals rose sharply from 25.9 % to 41.3 %
between 2005 and 2008 (Brazier et al., 2008). Patients
infected with 027 strains have more severe diarrhoea,
higher mortality and more recurrences (Goorhuis et al.,
2007; Hubert et al., 2007; Loo et al., 2005; Mooney, 2007;
Redelings et al., 2007).
A whole genome comparison method using microarrays
(comparative phylogenomics) demonstrated that most
NAP1/BI/027 isolates formed a single clonal lineage, termed
the hypervirulent clade (Griffiths et al., 2010; He et al., 2010;
Sebaihia et al., 2006). However, there were exceptions: a
single BI-9 (NAP1c) clustered outside the clonal lineage (He
et al., 2010; Stabler et al., 2006), identified later as PCR
ribotype 001 (He et al., 2010), and BI-14 (NAP1) was an
outlier to the hypervirulent clade (Stabler et al., 2006).
Interestingly, a previous report showed that not all NAP1
isolates are PCR ribotype 027. For example, strain CA10 was
NAP1, but PCR ribotype 019 (Killgore et al., 2008). MLVA
has been used to discriminate between isolates with identical
PCR ribotypes belonging to types 001, 017 and 027 (van den
Berg et al., 2007). Given that many of the PCR-ribotyped C.
difficile isolates in the US and UK are 027, it is important to
develop more accurate methods to distinguish between these
highly virulent strains. Recently, we fully sequenced the
genomes of two 027 isolates, an historic strain (CD196, the
original strain isolated in Paris in 1985) and a modern strain
(R20291, the index 027 strain isolated in the UK in 2006),
which revealed some genetic differences between them
(Stabler et al., 2009). More recently, Nycˇ et al. (2011)
reported an outbreak of CDI in the Czech Republic in which
the strains were PCR ribotype 176 and closely related to 027
strains. In this study, we determined phenotypic differences
in 26 presumed 027 strains from the US and the UK, isolated
between1988 and 2008, and re-evaluated their PCR ribotype.
We show that the UK and US 027 strains have distinct
motility and antibiotic resistance profiles and demonstrate
that some strains previously assumed to be 027 are different
PCR ribotypes such as 176, 198 and 244.
METHODS
The 26 human clinical isolates examined in this study are summarized
in Table 1. These include BI-1 to BI-15 (provided by Dale Gerding,
Hines VA Hospital, USA) and ten PCR ribotype 027 strains, 027-01 to
027-10 (provided by Derek J. Brown, Glasgow, Scotland). In addition,
M120 (provided by Denise Drudy, University College, Dublin) and
R20291 (provided by Jon Brazier, Cardiff, Wales) were used as controls.
C. difficile was routinely grown on Brazier’s CCEY agar (BioConnections)
containing 4 % egg yolk, C. difficile supplement (BioConnections) and
Table 1. Origin and source of C. difficile isolates (1998–2008)
Code Isolate reference number REA type Date isolated/received City, state/province Ribotype
BI-1 1675 BI-1 26/02/1988 Minneapolis, MN 027
BI-2 4272 BI-2 14/01/1991 Tucson, AZ 027
BI-3 4233 BI-3 14/12/1990 Minneapolis, MN 027
BI-4 5325 BI-4 10/02/1993 Minneapolis, MN 027
BI-5 5604 BI-5 25/08/1995 Albany, NY 027
BI-11 6296 BI-11 10/08/2001 Pittsburgh, PA 198
BI-10 6289 BI-10 10/08/2001 Pittsburgh, PA 027
BI-6 6336 BI-6 20/05/2003 Portland, OR 176
BI-7 6335 BI-7 20/05/2003 Portland, OR 027
BI-8 6367 BI-8 22/01/2004 Portland, ME 027
BI-6p 6413 BI-6p 09/09/2004 Atlanta, GA 027
BI-6p2 6431 BI-6p2 09/09/2004 New Jersey 027
BI-12 6425 BI-12 09/09/2004 Camp Hill, PA 027
BI-13 6430 BI-13 09/09/2004 New Jersey 027
BI-14 6432 BI-14 09/09/2004 New Jersey 244
BI-15 6436 BI-15 09/09/2004 New Jersey 027
R20291 R20291 2006 Aylesbury, England 027
027-01 20070031 13/12/2007 Dundee, Scotland 027
027-02 20070036 14/12/2007 Glasgow, Scotland 027
027-03 20080090 03/04/2008 Aberdeen, Scotland 027
027-04 20080107 07/04/2008 Dumfries, Scotland 027
027-05 20080195 22/05/2008 Ayshire, Scotland 027
027-06 20080238 05/06/2008 Dumbarton, Scotland 027
027-07 20080323 26/06/2008 Edinburgh, Scotland 027
027-08 20080533 06/08/2008 Dumbarton, Scotland 027
027-09 20080684 18/09/2008 Inverness, Scotland 027
027-10 20080783 22/10/2008 Glasgow, Scotland 027
M120 M120 2007 Ireland 078
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1 % defibrinated horse blood (TCS Biosciences), in brain heart infusion
(BHI) broth (Oxoid) supplemented with 2.5 % L-cysteine (Sigma
Aldrich) and C. difficile supplement (Fluka) and on blood agar (agar
base; Oxoid) supplemented with 7 % defibrinated horse blood (TCS
Biosciences). All cultures were grown from glycerol stocks in an
anaerobic atmosphere (10 % CO2, 10 % H2, 80 % N2) at 37 uC.
PCR ribotyping. PCR ribotyping was performed at least in duplicate.
Briefly, bacteria were harvested from 48 h anaerobic cultures on blood
agar. Cells were resuspended into a 5 % (w/v) solution of Chelex-100
(Bio-Rad) and heated to 100 uC for 12 min. The suspension was
separated by centrifugation (13 000 g for 12 min) and the supernatant
(10 ml) was added to a 100 ml PCR mixture containing 25 mM each
primer (P3 , 59-CTGGGGTGAAGTCGTAACAAGG-39; and P5 , 59-
GCGCCCTTTGTAGCTTGACC-39), 2.5 units Qiagen HotStar Taq
DNA polymerase per reaction, 0.4 mM dNTPs and 3.75 mM MgCl2
per reaction. The reaction mixture was subjected to 30 cycles of 9 uC
for 1 min, 92 uC for 1 min, 55 uC for 1 min and 72 uC for 1.5 min.
This was followed by 95 uC for 1 min, 55 uC for 45 s and 72 uC for
5 min. The PCR products were concentrated to 40 ml by heating at
75 uC. Electrophoresis was done at 100 mA in 3 % pre-cast Bio-Rad
0.5 % Tris/acetate-EDTA (TAE) agarose gels containing ethidium
bromide for 3.5 h at room temperature using pre-chilled TAE buffer.
Banding patterns were analysed using GelCompar software (Applied
Maths). R20291 was used as a PCR ribotype 027 control.
Antibiotic susceptibility test. A range of antibiotics were used to
determine the relative susceptibility to clindamycin, erythromycin,
chloramphenicol, tetracycline and fluoroquinolones (moxifloxacin,
gatifloxacin and levofloxacin). Strain C. difficile R20291 with known
MICs (Drudy et al., 2006; Stabler et al., 2009) was used as a control.
The interpretation of MIC results was based on the recommendations
given by the guidelines of the Clinical and Laboratory Standards
Institute (CLSI, 2008) for all antibiotics used in the present study
(Table 2).
Antibiotic susceptibility was determined using the Etest method in all
the cases, and the broth dilution method was also used to confirm
some of the Etest results. In this case antibiotics were supplied by
Sigma-Aldrich.
For the Etest method, a bacterial suspension in BHI to approximately
OD60050.5 (McFarland standard no. 3) was plated on blood agar and
allowed to dry for 15–30 min. Etest strips (AB Biodisk) were placed
onto agar surfaces. Agar plates were incubated anaerobically at 37 uC
for a further 24 h, and MICs were determined following the
manufacturer’s instructions. These were performed in triplicate and
R20291 was used as a control (Stabler et al., 2009).
In the broth dilution method, bacteria were grown in BHI broth
until an OD600 of 0.3. Antibiotics were dissolved according to the
manufacturer’s instructions (Sigma) and tested at a range of 1–128 mg
ml21. The MIC was taken as the lowest concentration to inhibit
completely visible growth after 24 h growth in an anaerobic chamber
at 37 uC. The final MICs were calculated as the mean among the three
performed replicates.
Motility assay. Motility assay was performed according to the Stabler
et al. (2009) protocol. Briefly, C. difficile cultures were grown
anaerobically for 1–2 days on BHI agar. BHI broth plus 0.05 % agar
was poured into 30 ml glass vials and placed into an anaerobic
chamber. Three single colonies were picked with a loop, inoculated
into the top 2–5 mm of BHI agar in the glass vial and left overnight in
the anaerobic chamber. The vials were then removed from the
chamber and photographed to record the motility. The maximum
stalactite length was taken as a measure for motility. The length of
those stalactite projections was scored as: ,1 cm, non-motile strains;
1–2 cm, motile strain; and .2 cm, highly motile strain. M120 is a
non-motile PCR ribotype 078 strain and R20291 is a motile PCR
ribotype 027 strain that were used as negative and positive controls,
respectively. Experiments were performed in triplicate.
Autoagglutination assay. An autoagglutination assay was per-
formed according to Stabler et al. (2009). C. difficile strains were
grown on BHI agar for 1–2 days and then inoculated into pre-
reduced 16 PBS to an OD600 of 1.0 (±0.1). Then, 2 ml in triplicate
was added to pre-reduced glass tubes and incubated for 24 h at 37 uC,
after which 1 ml was removed from the tube surface to measure the
OD600. The results were normalized to the starting OD using the
equation 1002[(final OD2starting OD)6100] to show the actual
autoagglutination percentage. Strain M120 was used as a positive
control as this strain shows more than 95 % autoagglutination;
R20291 was used as an autoagglutination negative control as it
exhibits a low percentage of autoagglutination. Experiments were
performed in triplicate.
Statistical analysis. Autoagglutination and motility data were
analysed by Tukey’s multiple-comparison test using Prism soft-
ware 9 version 4.0 (GraphPad Software). P,0.05 was considered
statistically significant.
RESULTS
PCR ribotyping
The strains examined in this study are summarized in
Table 1. The 16 US isolates were from multiple States
between 1988 and 2004 and pre-date the UK strains, which
include the UK index strain R20291 isolated in England
in 2006 and 10 strains isolated from different regions in
Scotland between 2007 and 2008.
Twenty-three of the 26 isolates were confirmed as PCR
ribotype 027. The other three strains were different PCR
ribotypes: BI-6 was PCR ribotype 176, BI-11 was PCR
ribotype 198 and BI-14 was PCR ribotype 244 (Table 1).
The PCR ribotype banding profile of 027 strains consisted
of seven distinct bands (Fig. 1a, b). Interestingly, the PCR
ribotype 198 (BI-11) and PCR ribotype 176 (BI-6) patterns
showed a high level of similarity to the PCR ribotype 027
pattern, differing by just a single band. However, strain BI-
14 (PCR ribotype 244) differed by the absence of a band
Table 2. Antibiotic breakpoints for anaerobes from Clinical and
Laboratory Standards Institute guidelines (CLSI, 2008)
Antibiotics Susceptible (mg ml”1) Resistant (mg ml”1)
Clindamycin ¡2 ¢8
Chloramphenicol ¡8 ¢32
Tetracycline ¡8 ¢32
Moxifloxacin ¡2 ¢8
Levofloxacin* ¡2 ¢8
Gatifloxacin ¡2 ¢8
*Levofloxacin breakpoints could be ¡2 mg ml21 (susceptible) and
¢8 mg ml21 (resistant) and erythromycin breakpoints could be
¡0.5 mg ml21 (susceptible) and ¢32 mg ml21 (resistant), as no
standard has been defined by the CLSI for anaerobes.
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and the addition of a different band (Fig. 1a, b). R20291
was used as a control for the 027 PCR ribotype.
Antibiotic resistance
Antibiotic susceptibility was tested for all isolates (Fig. 2).
The majority of PCR ribotype 027 strains exhibited either
intermediate resistance (8/26 strains) (4.5–6 mg ml21) or
full resistance (15/26 strains) (MIC ¢128 mg ml21) to
clindamycin as well as full resistance to erythromycin (18/
26 strains) (MIC ¢128 mg ml21). The only isolates
susceptible to both clindamycin and erythromycin were
BI-5 (MIC52 and 1.75 mg ml21, respectively) and BI-14
(MIC52 and 1.5 mg ml21, respectively). All UK strains and
some US strains were highly resistant to fluoroquinolones
(20/26 strains) (MIC ¢32 mg ml21). However, some US
strains were fluoroquinolone-susceptible to moxifloxacin
(7/26 strains) (MIC51 mg ml21), intermediately resistant
to levofloxacin (5/26 strains) (MIC54 mg ml21) and
gatifloxacin-susceptible and/or intermediately resistant (3/
26 and 4/26 strains, respectively) (Fig. 2).
BI-1 to BI-5 strains, isolated prior to 2003, showed either
intermediate resistance (MIC516 mg ml21) or were fully
resistant (MIC ¢128 mg ml21) to chloramphenicol,
whereas the other strains were susceptible to this antibiotic
in most cases (18/26 strains) (MIC55–12 mg ml21). Only
BI-7, BI-6p and BI-6p2 were resistant (MIC 18–24 mg
ml21) (Fig. 2). All the strains tested were susceptible to
tetracycline (MIC ,0.7 mg ml21). R20291 was used as a
control for antibiotic resistance.
Motility
There was clear and reproducible evidence of motility
among 027 isolates (Fig. 3). US strains (16/26 strains) were
motile (stalactite length range: 1.6–1.8 cm) whereas UK
strains (10/26 strains) were highly motile (stalactite length
range: 2.4–3 cm) (P,0.05) (Fig. 3). The M120 strain is a
non-motile negative control (0.7 cm) and R20291 is a
highly motile 027 strain positive control (3 cm) (Fig. 3).
Autoagglutination
Autoagglutination is often used to demonstrate charge
differences on bacterial cells that can be affected by the
presence of flagella and how they are modified (Howard et al.,
2009). The percentage of autoagglutination was tested for all
the isolates. We found a very heterogeneous representation of
the autoagglutination phenotype among the strains (Fig. 4).
DISCUSSION
Rates and severity of CDI have increased alarmingly in
recent years and are in part attributable to the emergence
and spread of the 027 clonal lineage (Goorhuis et al., 2007;
Hubert et al., 2007; Loo et al., 2005; Mooney, 2007). The 26
Fig. 1. PCR ribotype profiles obtained with C. difficile strains. (a) The PCR ribotype banding profile of 027 strains consisted of
seven distinct bands (see 027 control). The non-027 strains, PCR ribotype 198 (BI-11) and PCR ribotype 176 (BI-6), differed
by just a single band. However, strain BI-14 (PCR ribotype 244) differed by the absence of a band and the addition of a
different band. (b) PCR pattern of PCR ribotypes 027, 198, 176 and 244.
E. Valiente and others
52 Journal of Medical Microbiology 61
presumed PCR ribotype 027 strains investigated in this
study were isolated throughout the UK and the US over a
20-year period. The early strains (1988–2004) were from
different States in the US and the later strains (2006–2008)
were from the UK (Table 1), which presumably emerged
from North America. Interestingly, these isolates are
Fig. 2. Antibiotic resistance heat map. All 26
strains were tested for their susceptibility to
clindamycin, erythromycin, chloramphenicol,
tetracycline and fluoroquinolones (levofloxacin,
gatifloxacin, moxifloxacin). Black represents
resistant, grey represents intermediately res-
istant and white represents susceptible.
Fig. 3. Relative motility assays for C. difficile strains. Strains were inoculated into 0.05% BHI agar and incubated for 24 h in an
anaerobic chamber. Motility is visualized as stalactite projections. M120 and R20291 are negative and positive controls,
respectively. Bar, 1.2 cm.
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generally referred to as BI/NAP1/027, with the assumption
that BI types and NAP1 types are PCR ribotype 027.
However, we have shown that the REA type ‘BI’ and the
PFGE type NAP1 do not always correlate with PCR
ribotype 027. PCR ribotype analysis revealed that BI-6, BI-
11 and BI-14 were not PCR ribotype 027 as previously
presumed. BI-14 was an outlier strain in a previous study
(Stabler et al., 2006). In our study, BI-14 had two different
bands compared to PCR ribotype 027, being assigned as
PCR ribotype 244. However, the similarity of the PCR
ribotype banding pattern for BI-11 (PCR ribotype 198) and
BI-6 (PCR ribotype 176) was high. Slight band differences
between PCR ribotype 176 and presumed PCR ribotype
027 C. difficile isolates have also been observed in Austria
(A. Indra, personal communication in 2010) and more
recently in the Czech Republic and in Poland (Nycˇ et al.,
2011). Despite being different ribotypes, it is clear that the
BI-11 (PCR ribotype 198) and BI-6 (PCR ribotype 176)
strains are closely related to 027 strains and have previously
been placed in the same clade using comparative genome
microarray analyses (Stabler et al., 2006). High similarity in
PCR ribotyping pattern between 027 and other ribotypes
should be monitored, as strains from these ribotypes may
be as problematic as the hypervirulent 027 strains.
CDI is frequently linked to treatment with antibiotics which
provide an advantage for C. difficile survival (Delaney et al.,
2007). In this study, we showed that UK strains were resistant
to most of the antibiotics tested. However, US strains showed
a variable range of antibiotic resistance depending on the
antibiotic. It is a reasonable hypothesis that these changes in
antibiotic resistance profiles could be linked to the changes in
antibiotic prescription policy over time and in different
countries. The most noteworthy is the rise in resistance to
fluoroquinolones such as levofloxacin, gatifloxacin and
moxifloxacin. With few exceptions, antibiotic resistance in
C. difficile is transposon-mediated: erythromycin resistance
(ermB) is carried on Tn5398 (Hussain et al., 2005; Sebaihia
et al., 2006) or CTnCD11 (He et al., 2010), chloramphenicol
resistance (catD) is carried on Tn4453 (Lyras et al., 2004) and
tetracycline resistance is carried on Tn5397 (Hussain et al.,
2005). Previous studies identified a novel transposon in
R20291, CTn-027, encoding a chloramphenicol resistance
gene (CDR20291_3461) in some PCR ribotype 027 strains
(Stabler et al., 2009). However, all UK strains with the
exception of R20291 (used as a control) and some US strains
were chloramphenicol-susceptible with some exceptions,
indicating that the transmission of this transposon-mediated
antibiotic resistance might not be uniform throughout the
027 lineage. On the other hand, tetracycline resistance (tetM),
usually carried on Tn5397, was absent in all 26 strains tested.
Generally, resistance to macrolides (e.g. erythromycin) and
lincosamides (e.g. clindamycin) is mediated via the presence
of the ermB gene and it is more common in 027 isolates
(Solomon et al., 2011). Although 14 strains were erythro-
mycin- and clindamycin-resistant, TnCD11 carrying ermB
was only present in five of the BI isolates (BI-6, BI-7, BI-10,
BI-13 and BI-15) analysed by whole genome analysis (He
et al., 2010). This suggests an alternative mechanism for ermB
resistance in the 027 lineage. The development of antibiotic
resistance in modern 027 strains emphasizes the importance
of antibiotic susceptibility testing for the emergence of
antibiotic resistance.
The flagella-associated genes in strain 630 (PCR ribotype
012) are found in two loci, F1 and F3, separated by an inter-
flagella locus, F2 (Stabler et al., 2009). The level of sequence
identity in 027 strains compared to the 630 strain for the F1
and F3 region was high, but there were significant differences
in the F2 region (Stabler et al., 2009). This may provide a
genetic basis for the motility differences among 027 isolates
used in this study, but to date available genetic information
on the strains in this study cannot explain the difference in
motility between the 027 strains. Modifications in motility
Fig. 4. Relative autoagglutination of C. difficile strains. C. difficile strains were grown on BHI plates for 1–2 days, then
inoculated into pre-equilibrated PBS to an OD600 of 1.0 (±0.1). These were incubated for 24 h in pre-equilibrated glass tubes,
and then the OD600 was measured. The percentage autoagglutination was normalized to the starting OD600. The bars indicate
the percentage of cells autoagglutinating. M120 was used as a positive control.
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and antibiotic resistance between the 027 strains may reflect
a genetic change with respect to the flagella and glycosylation
loci as well as the loss and gain of transposons and the
accumulation of mutations over time. Such changes could be
beneficial for invasion, adhesion, access to nutrients and
general survival and transmissibility of C. difficile.
Understanding the evolution of clones such as the PCR
ribotype 027 will be important in predicting the early
emergence (or disappearance) of highly virulent C. difficile
strains and represents a current public health imperative. In
this study, phenotypic differences between the 26 UK and
US strains suggest that the PCR ribotype 027 is genetically
variable. It appears that the 176 and 198 ribotypes have
evolved recently from the 027 lineage. Thus there should be
a heightened awareness that the recently identified PCR
ribotypes 176 and 198 may be as problematic as the 027
strains.
ACKNOWLEDGEMENTS
We acknowledge the Wellcome Trust for funding this research.
M. D. C. and E. V. acknowledge the Health Protection Agency
Collaborating Centre at UCLH and the Fundacio´n Alfonso Martinez
Escudero, respectively, for funding. We thank Derek Brown, Dale
Gerding, Jon Brazier and Denise Drudy for provision of C. difficile
strains.
REFERENCES
Bartlett, J. G. (1994). Clostridium difficile: history of its role as an
enteric pathogen and the current state of knowledge about the
organism. Clin Infect Dis 18 (Suppl. 4), S265–S272.
Brazier, J. S., Raybould, R., Patel, B., Duckworth, G., Pearson, A.,
Charlett, A., Duerden, B. I. & HPA Regional Microbiology Network
(2008). Distribution and antimicrobial susceptibility patterns of
Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro
Surveill 13, pii:19000.
Calabi, E. & Fairweather, N. (2002). Patterns of sequence conser-
vation in the S-layer proteins and related sequences in Clostridium
difficile. J Bacteriol 184, 3886–3897.
CLSI (2008). Performance Standards for Antimicrobial Susceptibility
Testing; 18th Informational Supplement. M100-S18. Wayne, PA:
Clinical and Laboratory Standards Institute.
Delaney, J. A., Dial, S., Barkun, A. & Suissa, S. (2007). Antimicrobial
drugs and community-acquired Clostridium difficile-associated dis-
ease, UK. Emerg Infect Dis 13, 761–763.
Drudy, D., Quinn, T., O’Mahony, R., Kyne, L., O’Gaora, P. & Fanning, S.
(2006). High-level resistance to moxifloxacin and gatifloxacin asso-
ciated with a novel mutation in gyrB in toxin-A-negative, toxin-B-
positive Clostridium difficile. J Antimicrob Chemother 58, 1264–1267.
Eckert, C., Vromman, F. O., Halkovich, A. & Barbut, F. (2011).
Multilocus variable-number tandem repeat analysis: a helpful tool
for subtyping French Clostridium difficile PCR ribotype 027 isolates.
J Med Microbiol 60, 1088–1094.
Feuillet, V., Medjane, S., Mondor, I., Demaria, O., Pagni, P. P., Gala´n,
J. E., Flavell, R. A. & Alexopoulou, L. (2006). Involvement of Toll-like
receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci
U S A 103, 12487–12492.
Goorhuis, A. V. K. T., Van der Kooi, T., Vaessen, N., Dekker, F. W.,
Van den Berg, R., Harmanus, C., van den Hof, S., Notermans, D. W.
& Kuijper, E. J. (2007). Spread and epidemiology of Clostridium
difficile polymerase chain reaction ribotype 027/toxinotype III in The
Netherlands. Clin Infect Dis 45, 695–703.
Griffiths, D., Fawley, W., Kachrimanidou, M., Bowden, R., Crook, D. W.,
Fung, R., Golubchik, T., Harding, R. M., Jeffery, K. J. & other authors
(2010). Multilocus sequence typing of Clostridium difficile. J Clin
Microbiol 48, 770–778.
He, M., Sebaihia, M., Lawley, T. D., Stabler, R. A., Dawson, L. F.,
Martin, M. J., Holt, K. E., Seth-Smith, H. M., Quail, M. A. & other
authors (2010). Evolutionary dynamics of Clostridium difficile over
short and long time scales. Proc Natl Acad Sci U S A 107, 7527–
7532.
Hennequin, C., Janoir, C., Barc, M. C., Collignon, A. & Karjalainen, T.
(2003). Identification and characterization of a fibronectin-binding
protein from Clostridium difficile. Microbiology 149, 2779–2787.
Howard, S. L., Jagannathan, A., Soo, E. C., Hui, J. P., Aubry, A. J.,
Ahmed, I., Karlyshev, A., Kelly, J. F., Jones, M. A. & other authors
(2009). Campylobacter jejuni glycosylation island important in cell
charge, legionaminic acid biosynthesis, and colonization of chickens.
Infect Immun 77, 2544–2556.
Hubert, B. L. V., Loo, V. G., Bourgault, A. M., Poirier, L., Dascal, A.,
Fortin, E., Dionne, M. & Lorange, M. (2007). A portrait of the
geographic dissemination of the Clostridium difficile North American
pulsed-field type 1 strain and the epidemiology of C. difficile-
associated disease in Que´bec. Clin Infect Dis 44, 238–244.
Hussain, H. A., Roberts, A. P. & Mullany, P. (2005). Generation of an
erythromycin-sensitive derivative of Clostridium difficile strain 630
(630Dgerm) and demonstration that the conjugative transposon
Tn916DE enters the genome of this strain at multiple sites. J Med
Microbiol 54, 137–141.
Jagai, J. & Naumova, E. (2009). Clostridium difficile-associated disease
in the elderly, United States. Emerg Infect Dis 15, 343–344.
Just, I., Wilm, M., Selzer, J., Rex, G., von Eichel-Streiber, C., Mann, M.
& Aktories, K. (1995). The enterotoxin from Clostridium difficile
(ToxA) monoglucosylates the Rho proteins. J Biol Chem 270, 13932–
13936.
Just, I., Hofmann, F., Genth, H. & Gerhard, R. (2001). Bacterial
protein toxins inhibiting low-molecular-mass GTP-binding proteins.
Int J Med Microbiol 291, 243–250.
Killgore, G., Thompson, A., Johnson, S., Brazier, J., Kuijper, E.,
Pepin, J., Frost, E. H., Savelkoul, P., Nicholson, B. & other authors
(2008). Comparison of seven techniques for typing international
epidemic strains of Clostridium difficile: restriction endonuclease
analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus
sequence typing, multilocus variable-number tandem-repeat analysis,
amplified fragment length polymorphism, and surface layer protein A
gene sequence typing. J Clin Microbiol 46, 431–437.
Kuijper, E. J., Coignard, B., Brazier, J. S., Suetens, C., Drudy, D.,
Wiuff, C., Pituch, H., Reichert, P., Schneider, F. & other authors
(2007). Update of Clostridium difficile-associated disease due to PCR
ribotype 027 in Europe. Euro Surveill 12, E1–E2.
Lee, A., O’Rourke, J. L., Barrington, P. J. & Trust, T. J. (1986). Mucus
colonization as a determinant of pathogenicity in intestinal infection
by Campylobacter jejuni: a mouse cecal model. Infect Immun 51, 536–
546.
Loo, V. G. P. L., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D.,
Michaud, S., Bourgault, A. M., Nguyen, T., Frenette, C. & other
authors (2005). A predominantly clonal multi-institutional outbreak
of Clostridium difficile-associated diarrhea with high morbidity and
mortality. N Engl J Med 353, 2442–2449.
Emergence of PCR ribotypes from C. difficile 027
http://jmm.sgmjournals.org 55
Lyras, D., Adams, V., Lucet, I. & Rood, J. I. (2004). The large resolvase
TnpX is the only transposon-encoded protein required for transposi-
tion of the Tn4451/3 family of integrative mobilizable elements. Mol
Microbiol 51, 1787–1800.
Milton, D. L., O’Toole, R., Horstedt, P. & Wolf-Watz, H. (1996).
Flagellin A is essential for the virulence of Vibrio anguillarum.
J Bacteriol 178, 1310–1319.
Mooney, H. (2007). Annual incidence of MRSA falls in England, but
C. difficile continues to rise. BMJ 335, 958.
Morris, A. M., Jobe, B. A., Stoney, M., Sheppard, B. C., Deveney, C. W.
& Deveney, K. E. (2002). Clostridium difficile colitis: an increasingly
aggressive iatrogenic disease? Arch Surg 137, 1096–1100.
Moulton, R. C. & Montie, T. C. (1979). Chemotaxis by Pseudomonas
aeruginosa. J Bacteriol 137, 274–280.
Nycˇ, O., Pituch, H., Mateˇjkova´, J., Obuch-Woszczatynski, P. &
Kuijper, E. J. (2011). Clostridium difficile PCR ribotype 176 in the
Czech Republic and Poland. Lancet 377, 1407.
Pe´pin, J., Valiquette, L. & Cossette, B. (2005). Mortality attributable
to nosocomial Clostridium difficile-associated disease during an
epidemic caused by a hypervirulent strain in Quebec. CMAJ 173,
1037–1042.
Popoff, M. R., Rubin, E. J., Gill, D. M. & Boquet, P. (1988). Actin-
specific ADP-ribosyltransferase produced by a Clostridium difficile
strain. Infect Immun 56, 2299–2306.
Pruckler, J. M., Benson, R. F., Moyenuddin, M., Martin, W. T. & Fields,
B. S. (1995). Association of flagellum expression and intracellular
growth of Legionella pneumophila. Infect Immun 63, 4928–4932.
Redelings, M. D., Sorvillo, F. & Mascola, L. (2007). Increase in
Clostridium difficile-related mortality rates, United States, 1999-2004.
Emerg Infect Dis 13, 1417–1419.
Ricciardi, R., Rothenberger, D. A., Madoff, R. D. & Baxter, N. N.
(2007). Increasing prevalence and severity of Clostridium difficile
colitis in hospitalized patients in the United States. Arch Surg 142,
624–631, discussion 631.
Rupnik, M., Avesani, V., Janc, M., von Eichel-Streiber, C. & Delme´e, M.
(1998). A novel toxinotyping scheme and correlation of toxinotypes
with serogroups of Clostridium difficile isolates. J Clin Microbiol 36,
2240–2247.
Sebaihia, M., Wren, B. W., Mullany, P., Fairweather, N. F., Minton, N.,
Stabler, R., Thomson, N. R., Roberts, A. P., Cerden˜o-Ta´rraga, A. M. &
other authors (2006). The multidrug-resistant human pathogen
Clostridium difficile has a highly mobile, mosaic genome. Nat Genet
38, 779–786.
Solomon, K., Fanning, S., McDermott, S., Murray, S., Scott, L.,
Martin, A., Skally, M., Burns, K., Kuijper, E. & other authors (2011). PCR
ribotype prevalence and molecular basis of macrolide-lincosamide-
streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical
Clostridium difficile isolates. J Antimicrob Chemother 66, 1976–1982.
Stabler, R. A., Gerding, D. N., Songer, J. G., Drudy, D., Brazier, J. S.,
Trinh, H. T., Witney, A. A., Hinds, J. & Wren, B. W. (2006). Comparative
phylogenomics of Clostridium difficile reveals clade specificity and
microevolution of hypervirulent strains. J Bacteriol 188, 7297–7305.
Stabler, R. A., He, M., Dawson, L., Martin, M., Valiente, E., Corton, C.,
Lawley, T. D., Sebaihia, M., Quail, M. A. & other authors (2009).
Comparative genome and phenotypic analysis of Clostridium difficile
027 strains provides insight into the evolution of a hypervirulent
bacterium. Genome Biol 10, R102.
Tasteyre, A., Barc, M. C., Collignon, A., Boureau, H. & Karjalainen, T.
(2001). Role of FliC and FliD flagellar proteins of Clostridium difficile
in adherence and gut colonization. Infect Immun 69, 7937–7940.
van den Berg, R. J., Schaap, I., Templeton, K. E., Klaassen, C. H. &
Kuijper, E. J. (2007). Typing and subtyping of Clostridium difficile
isolates by using multiple-locus variable-number tandem-repeat
analysis. J Clin Microbiol 45, 1024–1028.
Waligora, A. J., Hennequin, C., Mullany, P., Bourlioux, P., Collignon, A.
& Karjalainen, T. (2001). Characterization of a cell surface protein of
Clostridium difficile with adhesive properties. Infect Immun 69, 2144–
2153.
E. Valiente and others
56 Journal of Medical Microbiology 61
